Therapeutic manufacturers can bring new products to market faster and more cost-effectively using Lotus.
The Lotus platform satisfies the need of CMOs to reduce the cost of biopharmaceutical manufacturing by providing genetically modified host cells that improve the efficiency of drug purification. These cells are compatible with existing validated manufacturing equipment and processes, and do not negatively affect upstream expression efficiencies. At Boston Mountain Biotech, we don’t design new drugs, we help manufacture drugs more efficiently.
Now that the Lotus platform has been developed for E. coli production strains, BMB is currently seeking industrial partners to expand the Lotus platform into CHO and yeast, as well as other production hosts.
For more detailed information, see our BMB Whitepaper 2017.